Navigation Links
Celleration Appoints Mark T. Wagner President and Chief Executive Officer
Date:7/1/2009

EDEN PRAIRIE, Minn., July 1 /PRNewswire/ -- Celleration, Inc., developer of the patented MIST Therapy(R) System, an innovative device that uses ultrasound to heal wounds, has named Mark T. Wagner as president and chief executive officer and member of Celleration's board of directors. Mr. Wagner brings a successful track record of developing and commercializing medical devices spanning 30 years to the Celleration team.

"We are delighted by the addition of Mark to the Celleration team," said Ed Spencer, Jr., Chairman of Affinity Capital Management and Chairman of Celleration's board of directors. "Mark brings a wealth of experience and a solid history of building companies and delivering results. We are absolutely confident in Mark's ability to take Celleration to its next stage of commercialization and build value for its shareholders."

Mr. Wagner has decades of leadership experience in the medical device field. Most recently, he co-founded and is Board Chairman of Orasi Medical, a spinout from the University of Minnesota that is developing a diagnostic tool for neurological diseases. Prior to co-founding Orasi, Wagner served as CEO at multiple companies including, ProVation Medical, Survivalink and Altiva. Over the course of his career, Mr. Wagner has held positions of Vice President and General Manager of Nellcor's Global Sleep Solutions Group and executive positions with GE Medical Systems. Mr. Wagner currently serves on the board of directors of BioMedix Inc. and Vital Medix. Mr. Wagner holds a BS in Business Administration from the University of Southern California.

Kevin Nickels, the previous CEO, will continue to serve as the Chief Technology and Business Development Officer. Mr. Spencer commented, "During his seven years as CEO, Kevin made a huge contribution to the development of the business and I am delighted that we will continue to have the benefit of his vision in his new role as Chief Technology and Business Development Officer."

About Celleration, Inc.:

Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology delivers non-contact, low-frequency, low-intensity ultrasound to the patient's injured soft tissue in a painless fashion. The chronic diabetic foot ulcer market had been the Company's initial focus. MIST Therapy(R) has since expanded to various hard to heal, chronic wounds benefiting from higher incidence of complete healing in less time than standard of care. The end results, improving patient outcomes at a lower cost to the health care industry. In addition to the Company's prospective, randomized, double-blind, sham-controlled multi-center study in diabetic foot ulcers, which resulted in a statistically significant improvement in the rate of wound closure and time to wound closure, numerous independent clinical researchers without funding from the Company has further validated this value proposition.

    Contacts:
    Chris Geyen, Chief Financial Officer
    952-224-8700

    Richard Lewis Communications, Inc.
    212-827-0020
    Andrew Mielach, Media
    amielach@rlcinc.com
    Cecelia Heer, Investors
    cheer@rlcinc.com


'/>"/>
SOURCE Celleration, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. XLHealth Appoints New Vice President of Contracting and Provider Relations
2. Wisconsin Tobacco Tax Increase Is Positive Step for Health, but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs
3. Verathon Inc. Appoints Kendall Stever as Chief Financial Officer
4. Tyco Electronics Appoints Cuong Do as Senior Vice President, Corporate Strategy & Business Development
5. Symmetry Medical Appoints Chairman and Two Directors
6. GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director
7. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
8. Cinergy Health Appoints Dr. Erika Schwartz as Medical Director
9. ThermoGenesis Appoints Chief Executive Officer J. Melville (Mel) Engle to Board of Directors
10. China Nepstar Chain Drugstore Appoints Chief Operating Officer
11. Darwin Appoints Becky Cox Vice President, Business Development, Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... , ... Offering the purest product of its kind, Swissx Labs AG has ... than the market has seen before. Swissx uses proprietary strains of hemp plants grown ... process for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. ...
(Date:4/26/2017)... ... 2017 , ... Journal of Oral Implantology – Tooth loss is ... dental health, including complications with speech, eating, and overcompensation of mouth due to the ... teeth. As the number of tooth replacements increase, it is imperative to design an ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business Research ... National Registry of Emergency Medical Technicians and welcomes this organization to the ... Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This award ...
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® ... ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively manage protein costs. “Soy ... cost savings as well as more stable pricing over time. Now it’s even ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... an agreement to be the preferred physical therapy provider for Derby City CrossFit, ... to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: